citation_journal,link,PMID
"Poulton A, Briody J, McCorquodale T, Melzer E, Herrmann M, Baur LA, et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? ‐ A prospective longitudinal study.  International Journal of Pediatric Endocrinology 2012;2012(1):30. [DOI: 10.1186/1687‐9856‐2012‐30; PMC3549744; PUBMED: 23216890]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23216890,23216890.0
"Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21890793,21890793.0
"Gross‐Tsur V, Joseph A, Shalev RS. Hallucinations during methylphenidate therapy.  Neurology 2004;63(4):753‐4. [PUBMED: 15326264]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15326264,15326264.0
"Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder.  Chinese Medical Journal 2011;124(20):3269‐74. [PUBMED: 22088519]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22088519,22088519.0
Pelham WE. The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?.  Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/10637677,10637677.0
"Mahmoudi‐Gharaei J, Dodangi N, Tehrani‐Doost M, Faghihi T. Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open‐label study.  Human Psychopharmacology 2011;26(2):155‐60. [DOI: 10.1002/hup.1188; PUBMED: 21455975]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21455975,21455975.0
"Conners CK, Epstein JN, March JS, Angold A, Wells KC, Klaric J, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis.  Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11211364,11211364.0
"Barbaresi WJ, Colligan RC, Weaver AL, Voigt RG, Kilian JM, Katusic SK. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study.  Pediatrics 2013;132(4):637‐44. [DOI: 10.1542/peds.2012‐2354]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23460687,23460687.0
"Arun P, Sahni S. Methylphenidate and suicidal ideation: report of two cases.  Indian Journal of Psychiatry 2014;56(1):79‐81. [DOI: 10.4103/0019‐5545.124721; PMC3927251]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24574564,24574564.0
"Stevens JR, George RA, Fusillo S, Stern TA, Wilens TE. Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation.  Journal of Child and Adolescent Psychopharmacology 2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20166796,20166796.0
"Yoshimasu K, Barbaresi WJ, Colligan RC, Kilian JM, Voigt RG, Weaver AL, Katusic SK. Written‐language disorder among children with and without ADHD in a population‐based birth cohort..  Pediatrics 2011;128(3):605‐12. CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21859915,21859915.0
"Wang LJ, Huang YS, Chiang YL, Hsiao CC, Shang ZY, Chen CK. Clinical symptoms and performance on the Continuous Performance Test in children with attention deficit hyperactivity disorder between subtypes: a natural follow‐up study for 6 months.  BMC Psychiatry 2011;11:65. [DOI: 10.1186/1471‐244X‐11‐65; PMC3111344; PUBMED: 21504587]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21504587,21504587.0
MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment.  Pediatrics 2004;113(4):762‐9. [PUBMED: 15060225] CENTRAL,https://www.ncbi.nlm.nih.gov/pubmed/15060225,15060225.0
"Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15662146,15662146.0
"Hammerness P, Biederman J, Petty C, Henin A, Moore CM. Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention‐deficit hyperactivity disorder: a controlled pilot study. CNS Neuroscience and Therapeutics. P. Hammerness, Massachusetts General Hospital, 185 Alewife Brook Parkway, Suite 2000, Cambridge, MA 02138, United States. E‐mail: phammerness@partners.org: Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom), 2012; Vol. 18, issue 1:34‐40. [DOI: 10.1111/j.1755‐5949.2010.00226.x; PMC4084790; PUBMED: 21143432]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21143432,21143432.0
Hechtman L. Effects of treatment on the overall functioning of children with ADHD.  Journal of the Canadian Academy of Child and Adolescent Psychiatry 2009;14(Suppl 1):10‐5. [PMC2547092]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/19030519,19030519.0
"Kemner JE, Starr HL, Ciccone PE, Hooper‐Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.  Advances in Therapy 2005;22(5):498‐512. [PUBMED: 16418159] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16418159,16418159.0
"Williams LM, Hermens DF, Palmer D, Kohn M, Clarke S, Keage H, et al. Misinterpreting emotional expressions in attention‐deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects.  Biological Psychiatry 2008;63(10):917‐26. [DOI: 10.1016/j.biopsych.2007.11.022; PUBMED: 18272140] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18272140,18272140.0
"Abikoff H. Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11294070,11294070.0
"Mayes SD, Crites DL, Bixler EO, Humphrey FJ, Mattison RE. Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status.  Developmental Medicine and Child Neurology 1994;36(12):1099‐107. [PUBMED: 7525394] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/7525394,7525394.0
"Döpfner M, Breuer D, Walter D, Rothenberger A. An observational study of once‐daily modified‐release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality‐of‐life outcomes.  European Child and Adolescent Psychiatry 2011;20(Suppl 2):S277‐88. [DOI: 10.1007/s00787‐011‐0205‐1; PMC3098980; PUBMED: 21901414] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21901414,21901414.0
"Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS‐methylphenidate compared to usual care with immediate‐release methylphenidate in ADHD.  Canadian Journal of Clinical Pharmacology 2006;13(1):e50‐62. [PUBMED: 16456216] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16456216,16456216.0
"Nolan EE, Gadow KD. Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphenidate.  Journal of the American Academy of Child and Adolescent Psychiatry 1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9136493,9136493.0
"Bruxel EM, Salatino‐Oliveira A, Genro JP, Zeni CP, Polanczyk GV, Chazan R, et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention‐deficit/hyperactivity disorder treated with methylphenidate.  Pharmacogenomics Journal 2013;13(5):476‐80. [DOI: 10.1038/tpj.2012.25; PUBMED: 22688218]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22688218,22688218.0
"Nymark TB, Hovland A, Bjørnstad H, Nielsen EW. A young man with acute dilated cardiomyopathy associated with methylphenidate.  Vascular Health and Risk Management 2008;4(2):477‐9. [PMC2496981; PUBMED: 18561524]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18561524,18561524.0
"Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD.  Journal of Attention Disorders 2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17494833,17494833.0
"Bukstein OG, Arnold LE, Landgraf JM, Hodgkins P. Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?.  Child and Adolescent Psychiatry and Mental Health 2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20003260,20003260.0
"Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations.  Journal of Child Neurology 2009;24(8):1005‐7. [DOI: 10.1177/0883073808331357; PUBMED: 19502578]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19502578,19502578.0
Niederhofer H. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?.  Psychiatria Danubina 2009;21(3):330. [PUBMED: 19794351]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/19794351,19794351.0
"Kraut AA, Langner I, Lindemann C, Banaschewski T, Petermann U, Petermann F, et al. Comorbidities in ADHD children treated with methylphenidate: a database study.  BMC Psychiatry 2013;13:11. [DOI: 10.1186/1471‐244X‐13‐11; PMC3544568; PUBMED: 23294623]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23294623,23294623.0
"Harstad EB, Weaver AL, Katusic SK, Colligan RC, Kumar S, Chan E, et al. ADHD, stimulant treatment, and growth: a longitudinal study.  Pediatrics. 2014;134(4):935‐44. [DOI: 10.1542/peds.2014‐0428; PUBMED: 25180281]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25180281,25180281.0
"Woolley JB, Heyman I. Dexamphetamine for obsessive‐compulsive disorder.  American Journal of Psychiatry 2003;160(1):183. CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12505824,12505824.0
"Swanson JM, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw SP, et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details.  Journal of Attention Disorders 2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18573924,18573924.0
"Berek M, Kordon A, Hargarter L, Mattejat F, Slawik L, Rettig K, et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?.  Child & Adolescent Psychiatry & Mental Health 2011;5(1):26. [DOI: 10.1186/1753‐2000‐5‐26]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21791096,21791096.0
"Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long‐term methylphenidate therapy in children with comorbid attention‐deficit hyperactivity disorder and chronic multiple tic disorder.  Archives of General Psychiatry 1999;56(4):330‐6. [PUBMED: 10197827] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/10197827,10197827.0
"Lamberti M, Italiano D, Guerriero L, D'Amico G, Siracusano R, Ingrassia M, et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder.  Neuropsychiatric Disease and Treatment 2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26056451,26056451.0
"Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate‐release methylphenidate: a 36‐month naturalistic study.  Journal of Child and Adolescent Psychopharmacology 2009;19(6):673‐81. [DOI: 10.1089/cap.2008.0146; PUBMED: 20035585]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20035585,20035585.0
"Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L. Efficacy of methylphenidate hydrochloride extended‐release capsules (Aptensio XRTM) in children and adolescents with attention‐deficit/hyperactivity disorder: a phase III, randomized, double‐blind study.  CNS Drugs 2015;29(4):331‐40.  CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25877989,25877989.0
"Yang P, Chung LC, Chen CS, Chen CC. Rapid improvement in academic grades following methylphenidate treatment in attention‐deficit hyperactivity disorder.  Psychiatry and Clinical Neurosciences 2004;58(1):37‐41. [PUBMED: 14678455]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/14678455,14678455.0
"Findling RL, Katic A, Rubin R, Moon E, Civil R, Li Y. A 6‐month, open‐label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2010;20(5):366‐75. [DOI: 10.1089/cap.2009.0122; PUBMED: 20973707]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20973707,20973707.0
"Gadow D, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention‐deficit hyperactivity disorder in children with tic disorder.  Annual Progress in Child Psychiatry and Child Development 1995;52(6):494‐522. [PUBMED: 7771914] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/7771914,7771914.0
"Alpaslan AH, Coşkun KŞ, Kocak U, Gorücü Y. Stuttering associated with the use of short‐acting oral methylphenidate.  Klinik Psikofarmakoloji Bülteni [Journal of Clinical Psychopharmacology] 2015;35(6):739‐41. [DOI: 10.1097/JCP.0000000000000403; PUBMED: 26436866]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26436866,26436866.0
"Germinario EP, Arcieri R, Bonati M, Zuddas A, Masi G, Vella S, et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.  Journal of Child and Adolescent Psychopharmacology 2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24024538,24024538.0
"Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.  Child: Care, Health and Development 2006;32(5):575‐83. [DOI: 10.1111/j.1365‐2214.2006.00631.x; PUBMED: 16919137]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16919137,16919137.0
"Greene RW, Ablon JS. What does the MTA study tell us about effective psychosocial treatment for ADHD?.  Journal of Clinical Child Psychology 2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11294069,11294069.0
"Sobanski E, Döpfner M, Ose C, Fischer R. A non‐interventional study of extended‐release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment.  Attention Deficit and Hyperactivity Disorders 2013;5(4):387‐95. [DOI: 10.1007/s12402‐013‐0113‐y; PUBMED: 23794192]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23794192,23794192.0
"Goetz M, Prihodova I, Hrdlicka M. Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7‐year old girl.  Neuro Endocrinology Letters 2011;32(5):619‐22. [PUBMED: 22167138]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22167138,22167138.0
"Hollis CP, Thompson A. Acute dyskinesia on starting methylphenidate after risperidone withdrawal.  Pediatric Neurology 2007;37(4):287‐8. [DOI: 10.1016/j.pediatrneurol.2007.05.017; PUBMED: 17903675]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17903675,17903675.0
"Dupuy FE, Clarke AR, Barry RJ, McCarthy R, Selikowitz M. EEG coherence in girls with attention‐deficit/hyperactivity disorder: stimulant effects in good responders.  International Journal of Psychophysiology 2008;70(3):151‐7. [DOI: 10.1016/j.ijpsycho.2008.07.012; PUBMED: 18708101]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18708101,18708101.0
"Wilens TE, Boellner SW, López FA, Turnbow JM, Wigal SB, Childress AC, et al. Varying the wear time of the methylphenidate transdermal system in children with attention‐deficit/hyperactivity disorder.  Journal of the American Academy of Child and Adolescent Psychiatry 2008;47(6):700‐8. [DOI: 10.1097/CHI.0b013e31816bffdf; PUBMED: 18434918] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18434918,18434918.0
"Lee SH, Seo WS, Sung HM, Choi TY, Kim SY, Choi SJ, et al. Effect of methylphenidate on sleep parameters in children with ADHD.  Psychiatry Investigation 2012;9(4):384‐90. [DOI: 10.4306/pi.2012.9.4.384; PMC3521116] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23251204,23251204.0
"Katusic SK, Barbaresi W, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Case definition in epidemiologic studies of ADHD.  Annals of Epidemiology 2005;15(6):430‐7. [DOI: 10.1016/j.annepidem.2004.12.004; PUBMED: 15967390]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15967390,15967390.0
"Green T, Weinberger R, Diamond A, Berant M, Hirschfeld L, Frisch A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome.  Journal of Child and Adolescent Psychopharmacology 2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22149470,22149470.0
"Tekin U, Soyata AZ, Oflaz S. Acute focal dystonic reaction after acute methylphenidate treatment in an adolescent patient.  Journal of Clinical Psychopharmacology 2015;35(2):209‐11. [DOI: 10.1097/JCP.0000000000000266; PUBMED: 25607477]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25607477,25607477.0
"Molina BS, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17667481,17667481.0
"Schmidt JK, Plück J, Gontard A. Waiver of EEG diagnostics prior to and during methylphenidate therapy: dangerous or justifiable? [Verzicht auf eine EEG‐Diagnostik vor Beginn und unter einer Therapie mit Methylphenidat: gefährlich oder gerechtfertigt?].  Zeitschrift fur Kinder‐ und Jugendpsychiatrie und Psychotherapie 2002;30(4):295‐302. [DOI: 10.1024/1422‐4917.30.4.295]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12474320,12474320.0
"Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V. Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD.  Pediatrics 2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20837589,20837589.0
"Jafarinia M, Mohammadi MR, Modabbernia A, Ashrafi M, Khajavi D, Tabrizi M, et al. Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study. Human Psychopharmacology2012; Vol. 27, issue 4:411‐8. [DOI: 10.1002/hup.2242; PUBMED: 22806822] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22806822,22806822.0
"Kim HW, Kim SO, Shon S, Lee JS, Lee HJ, Choi JH. Effect of methylphenidate on height and weight in Korean children and adolescents with attention‐deficit/hyperactivity disorder: a retrospective chart review.  Journal of Child and Adolescent Psychopharmacology 2014;24(8):448‐53. [DOI: 10.1089/cap.2014.0025; PUBMED: 25285915]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25285915,25285915.0
"Ghanizadeh A, Sayyari Z, Mohammadi MR. Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial.  Iranian Journal of Psychiatry 2013;8(3):108‐12. [PMC3887226; PUBMED: 24454418] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24454418,24454418.0
"Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention‐deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.  Journal of Child Neurology 2003;18(2):109‐12. [DOI: 10.1177/08830738030180020601; PUBMED: 12693777]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12693777,12693777.0
"Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, et al. Methylphenidate side effect profile is influenced by genetic variation in the attention‐deficit/hyperactivity disorder‐associated CES1 gene.  Journal of Child and Adolescent Psychopharmacology 2013;23(10):655‐64. [DOI: 10.1089/cap.2013.0032; PUBMED: 24350812]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24350812,24350812.0
"Su Y, Li H, Chen Y, Fang F, Xu T, Lu H, et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder.  Journal of Clinical Psychopharmacology 2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26267421,26267421.0
"Pierce D, Katic A, Buckwalter M, Webster K. Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.  Journal of Clinical Psychopharmacology 2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20814325,20814325.0
"Niederhofer H. Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine.  Medical Hypotheses 2011;76(5):764‐5. [DOI: 10.1016/j.mehy.2011.02.011; PUBMED: 21397406]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21397406,21397406.0
"Panei P, Arcieri R, Vella S, Bonati M, Martini N, Zuddas A. Italian attention‐deficit/hyperactivity disorder registry.  Pediatrics 2004;114(2):514. [PUBMED: 15286248]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15286248,15286248.0
"Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, et al. How common is attention‐deficit/hyperactivity disorder? Incidence in a population‐based birth cohort in Rochester, Minn.  Archives of Pediatrics and Adolescent Medicine 2002;156(3):217‐24. [PUBMED: 11876664]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11876664,11876664.0
"Chazan R, Borowski C, Pianca T, Ludwig H, Rohde LA, Polanczyk G. Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention‐deficit/hyperactivity disorder? A naturalistic study from a developing count.  Journal of Clinical Psychopharmacology 2011;31(3):309‐17. [DOI: 10.1097/JCP.0b013e318217b4df; PUBMED: 21508864]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21508864,21508864.0
"McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study.  Journal of the American Academy of Child and Adolescent Psychiatry 2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/27453079,27453079.0
"Wiguna T, Guerrero AP, Wibisono S, Sastroasmoro S. Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22318191,22318191.0
"Yilmaz AE, Donmez A, Orun E, Tas T, Isik B, Sonmez FM. Methylphenidate‐induced acute orofacial and extremity dyskinesia.  Journal of Child Neurology 2013;28(6):778‐80. [DOI: 10.1177/0883073812449905; PUBMED: 22791547]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22791547,22791547.0
"Efron D, Jarman FC, Barker MJ. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.  Journal of Paediatrics and Child Health 1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9633980,9633980.0
"Lahat E, Weiss M, Ben‐Shlomo A, Evans S, Bistritzer T. Bone mineral density and turnover in children with attention‐deficit hyperactivity disorder receiving methylphenidate.  Journal of Child Neurology 2000;15(7):436‐9. [DOI: 10.1177/088307380001500702; PUBMED: 10921512]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/10921512,10921512.0
"Rappaport N, Coffey B. Psychopharmacology in the school setting: therapeutic challenges in an adolescent with attention deficit hyperactivity disorder, possible bipolar disorder, and other comorbidity.  Journal of Child and Adolescent Psychopharmacology 2004;14(1):3‐7. [DOI: 10.1089/104454604773840418; PUBMED: 15142385]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15142385,15142385.0
"Salatino‐Oliveira A, Genro JP, Zeni C, Polanczyk GV, Chazan R, Guimarães AP, et al. Catechol‐O‐methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention‐deficit/hyperactivity disorder.  Biological Psychiatry 2011;70(3):216‐21. [DOI: 10.1016/j.biopsych.2011.03.025; PUBMED: 21550019]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21550019,21550019.0
"Mellon MW, Natchev BE, Katusic SK, Colligan RC, Weaver AL, Voigt RG, et al. Incidence of enuresis and encopresis among children with attention‐deficit/hyperactivity disorder in a population‐based birth cohort.  Academic Pediatrics 2013;13(4):322‐7. [DOI: 10.1016/j.acap.2013.02.008; PMC3886550; PUBMED: 23680296]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23680296,23680296.0
"Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B, Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?.  Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16670649,16670649.0
"El‐Zein RA, Abdel‐Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, et al. Cytogenetic effects in children treated with methylphenidate.  Cancer Letters 2005;230(2):284‐91. [DOI: 10.1016/j.canlet.2005.01.003; PUBMED: 16297714]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16297714,16297714.0
"Thorell LB, Dahlström K. Children's self‐reports on perceived effects on taking stimulant medication for ADHD.  Journal of Attention Disorders 2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18685139,18685139.0
"Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder.  Progress in Neuro‐Psychopharmacology and Biological Psychiatry 2007;31(1):210‐6. [DOI: 10.1016/j.pnpbp.2006.09.002; PUBMED: 17046131]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17046131,17046131.0
"Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder.  International Clinical Psychopharmacology 2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20093941,20093941.0
"Guerreiro MM, Montenegro MA, Piva RT, Moura‐Ribeiro MV. Attention deficit disorder: treatment with methylphenidate [Distúrbio do déficit de atenção: tratamento com metilfenidato].  Arquivos de Neuro‐Psiquiatria 1996;54(1):25‐9. [DOI: 10.1590/S0004‐282X1996000100004]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/8736140,8736140.0
"Stein D, Pat‐Horenczyk R, Blank S, Dagan Y, Barak Y, Gumpel TP. Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder.  Journal of Learning Disabilities 2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15493323,15493323.0
Pae CU. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder.  Progress in Neuro‐Psychopharmacology and Biological Psychiatry 2007;31(5):1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.018]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/17493730,17493730.0
"Balázs J, Dallos G, Keresztény A, Czobor P, Gádoros J. Methylphenidate treatment and dyskinesia in children with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2011;21(2):133‐8. [DOI: 10.1089/cap.2010.0030; PUBMED: 21486166]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21486166,21486166.0
"Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B. Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH.  Postgraduate Medicine 2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21904084,21904084.0
"Fernández‐Fernández MA, Rufo‐Campos M, Mateos‐Checa R, Muñoz‐Cabello B, Madruga‐Garrido M, Blanco‐Martínez B. Cardiovascular side effects secondary to treatment with methylphenidate [Reacciones adversas cardiovasculares secundarias al tratamiento con metilfenidato].  Revista de Neurologia 2010;50(9):573‐4. [PUBMED: 20443179]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20443179,20443179.0
"MacDonald Fredericks E, Kollins SH. A pilot study of methylphenidate preference assessment in children diagnosed with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2005;15(5):729‐41. [DOI: 10.1089/cap.2005.15.729; PUBMED: 16262590]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16262590,16262590.0
"Richters JE, Arnold LE, Jensen PS, Abikoff H, Conners CK, Greenhill LL, et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale.  Journal of the American Academy of Child and Adolescent Psychiatry 1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/7665456,7665456.0
"Buchmann J, Wolters A, Haessler F, Bohne S, Nordbeck R, Kunesch E. Disturbed transcallosally mediated motor inhibition in children with attention deficit hyperactivity disorder (ADHD).  Clinical Neurophysiology 2003;114(11):2036‐42. [PUBMED: 14580601]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/14580601,14580601.0
"Dubnov‐Raz G, Perry A, Berger I. Body mass index of children with attention‐deficit/hyperactivity disorder.  Journal of Child Neurology 2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20929910,20929910.0
"Grossman LK, Grossman NJ. Methylphenidate and idiopathic thrombocytopenic purpura‐‐is there an association?.  Journal of Family Practice 1985;20(3):302‐4. [PUBMED: 4038730]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/4038730,4038730.0
"Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial.  Journal of the American Academy of Child and Adolescent Psychiatry 2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12108801,12108801.0
"Machado A, Cerqueira J, Rodrigues M, Soares‐Fernandes J. Is methylphenidate‐induced chorea responsive to chlorpromazine?.  Journal of Neuropsychiatry and Clinical Neurosciences 2010;22(3):352.e20. [DOI: 10.1176/jnp.2010.22.3.352.e20; PUBMED: 20686158]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20686158,20686158.0
"Khajehpiri Z, Mahmoudi‐Gharaei J, Faghihi T, Karimzadeh I, Khalili H, Mohammadi M. Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center.  Journal of Research in Pharmacy Practice 2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25535621,25535621.0
"Munk K, Gormsen L, Kim WY, Andersen NH. Cardiac arrest following a myocardial infarction in a child treated with methylphenidate.  Case Reports in Pediatrics 2015;2015:905097. [DOI: 10.1155/2015/905097]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26221559,26221559.0
"Tang CS, Chou WJ, Cheng AT. Osmotic release oral system (OROS) methylphenidate‐induced double incontinence: a case report.  Primary Care Companion to the Journal of Clinical Psychiatry 2010;12(3):PCC.09l00870. [DOI: 10.4088/PCC.09l00870pur; PMC2947529]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20944782,20944782.0
"Faraone SV, Giefer EE. Long‐term effects of methylphenidate transdermal delivery system treatment of ADHD on growth.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(9):1138‐47. [DOI: 10.1097/chi.0b013e31806ad1d7; PUBMED: 17712237]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17712237,17712237.0
"Cakin‐Memik N, Yildiz O, Sişmanlar SG, Karakaya I, Ağaoğlu B. Priapism associated with methylphenidate: a case report.  Turkish Journal of Pediatrics 2010;52(4):430‐4. [PUBMED: 21043394]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21043394,21043394.0
"Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial.  Journal of Clinical Pharmacy and Therapeutics 2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15068402,15068402.0
"Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.  Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11211366,11211366.0
"Wigal SB, Wilens TE, Wolraich M, Lerner M. Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results.  Pediatrics 2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17548486,17548486.0
"Larrañaga‐Fragoso P, Noval S, Rivero JC, Boto‐de‐los‐Bueis A. The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder.  Journal of AAPOS 2015;19(4):322‐6. [DOI: 10.1016/j.jaapos.2015.04.005; PUBMED: 26235791]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26235791,26235791.0
"Moungnoi P, Maipang P. Long‐term effects of short‐acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.  Journal of the Medical Association of Thailand 2011;94(Suppl 3):S158‐63. [PUBMED: 22043770]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22043770,22043770.0
"Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices.  Archives of General Psychiatry 1997;54(9):865‐70. [PUBMED: 9294378] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9294378,9294378.0
"Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, Ghaleiha A, Akhondzadeh S. Acetyl‐L‐carnitine as an adjunctive therapy in the treatment of attention‐deficit/hyperactivity disorder in children and adolescents: a placebo‐controlled trial.  Child Psychiatry and Human Development 2011;42(3):367‐75. [DOI: 10.1007/s10578‐011‐0220‐y; PUBMED: 21336630] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21336630,21336630.0
"Agarwal V, Sitholey P. Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report.  Journal of the Canadian Academy of Child and Adolescent Psychiatry 2008;17(3):160. [PMC2527769]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18769587,18769587.0
"Tasdelen BI, Karakaya E, Oztop DB. Effects of atomoxetine and osmotic release oral system‐methylphenidate on executive functions in patients with combined type attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2015;25(6):494‐500. [DOI: 10.1089/cap.2014.0155; PUBMED: 26218871] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26218871,26218871.0
"Witt KL, Shelby MD, Itchon RN, Faircloth M, Kissling GE, Chrisman AK, et al. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD.  Journal of the American Academy of Child and Adolescent Psychiatry 2008;47(12):1375‐83. [DOI: 10.1097/CHI.0b013e3181893620; PMC2807376; PUBMED: 18978633] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18978633,18978633.0
"Panei P, Arcieri R. ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza].  Recenti Progressi in Medicina 2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23801229,23801229.0
"Bereket A, Turan S, Karaman MG, Haklar G, Ozbay F, Yazgan MY. Height, weight, IGF‐I, IGFBP‐3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment.  Hormone Research 2005;63(4):159‐64. [DOI: 10.1159/000084683; PUBMED: 15795512]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15795512,15795512.0
"Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry.  CNS Drugs 2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26293742,26293742.0
"Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study.  Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12649629,12649629.0
"Buchmann J, Gierow W, Weber S, Hoeppner J, Klauer T, Wittsock M, et al. Modulation of transcallosally mediated motor inhibition in children with attention deficit hyperactivity disorder (ADHD) by medication with methylphenidate (MPH).  Neuroscience Letters 2006;405(1‐2):14‐8. [DOI: 10.1016/j.neulet.2006.06.026; PUBMED: 16815631]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16815631,16815631.0
"Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y. Comparative study of OROS‐MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. International Journal of Neuropsychopharmacology2012; Vol. 15, issue 1:15‐26. [DOI: 10.1017/S1461145711001490; PUBMED: 22017969] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22017969,22017969.0
"Ririe DG, Ririe KL, Sethna NF, Fox L. Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents.  Paediatric Anaesthesia 1997;7(1):69‐72. [PUBMED: 9041578]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9041578,9041578.0
"Grcevich S, Rowane WA, Marcellino B, Sullivan‐Hurst S. Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2001;11(1):35‐41. [DOI: 10.1089/104454601750143401; PUBMED: 11322743]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11322743,11322743.0
"Durá‐Travé T, Yoldi‐Petri ME, Zardoya‐Santos P. Nutrition and attention deficit hyperactivity disorder: developmental follow‐up of the anthropometric variables of a group of patients receiving treatment with osmotic controlled‐release methylphenidate [Nutrición y trastorno por déficit de atención/hiperactividad: seguimiento evolutivo de las variables antropométricas de un grupo de pacientes en tratamiento con metilfenidato de liberación osmótica].  Revista de Neurologia 2011;53(5):257‐64. [PUBMED: 21796603]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21796603,21796603.0
"Panei P, Arcieri R, Vella S, Bonati M, Martini N, Zuddas A. Italian attention‐deficit/hyperactivity disorder registry.  Pediatrics 2004;114(2):514. [PUBMED: 15286248]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15286248,15286248.0
"Garg J, Arun P, Chavan BS. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder.  International Journal of Applied and Basic Medical Research 2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26097819,26097819.0
"Sprafkin J, Gadow KD. Double‐blind versus open evaluations of stimulant drug response in children with attention‐deficit hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 1996;6(4):215‐28. [DOI: 10.1089/cap.1996.6.215; PUBMED: 9231315] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9231315,9231315.0
"Efron D, Jarman FC, Barker MJ. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial.  Pediatrics 1997;100(6):E6. [PUBMED: 9382907] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9382907,9382907.0
MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder.  Pediatrics 2004;113(4):754‐61. [PUBMED: 15060224] CENTRAL,https://www.ncbi.nlm.nih.gov/pubmed/15060224,15060224.0
Ghanizadeh A. Excessive talking triggered by methylphenidate in a boy with ADHD.  Pharmacopsychiatry 2009;42(1):35‐6. [DOI: 10.1055/s‐0028‐1083821; PUBMED: 19153945]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/19153945,19153945.0
"Dirksen SJ, D'Imperio JM, Birdsall D, Hatch SJ. A postmarketing clinical experience study of Metadate CD.  Current Medical Research and Opinion 2002;18(7):371‐80. [PUBMED: 12487502]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12487502,12487502.0
"Kim HJ, Yang J, Lee MS. Changes of heart rate variability during methylphenidate treatment in attention‐deficit hyperactivity disorder children: a 12‐week prospective study.  Yonsei Medical Journal 2015;56(5):1365‐71. [DOI: 10.3349/ymj.2015.56.5.1365; PMC4541668]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26256981,26256981.0
"Lee MS, Lee SI, Hong SD, Kim JH, Choi J, Joung YS. Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study.  Journal of Child and Adolescent Psychopharmacology 2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23347125,23347125.0
"Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.  Comprehensive Psychiatry 2001;42(3):228‐33. [DOI: 10.1053/comp.2001.23145; PUBMED: 11349243]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11349243,11349243.0
"Langevin R, Ramdé J. Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation.  Journal of the Canadian Academy of Child and Adolescent Psychiatry 2012;21(1):53‐8. [PMC3269251]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22299015,22299015.0
Sabuncuoglu O. Risperidone‐to‐methylphenidate switch reaction in children: three cases.  Journal of Psychopharmacology 2007;21(2):216‐9. [DOI: 10.1177/0269881107069466; PUBMED: 17329303]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/17329303,17329303.0
"McLaren JL, Cauble S, Barnett RJ. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.  Journal of Clinical Psychopharmacology 2010;30(1):77‐8. [DOI: 10.1097/JCP.0b013e3181c92eb2; PUBMED: 20075654]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20075654,20075654.0
"Didoni A, Sequi M, Panei P, Bonati M, Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder.  European Journal of Clinical Pharmacology 2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21538145,21538145.0
Rostain AL. Sleep disturbances and ADHD medications.  Current Psychiatry Reports 2007;9(5):399‐400. [PUBMED: 17915079] CENTRAL   Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/17915079,17915079.0
"Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings.  Journal of the American Academy of Child and Adolescent Psychiatry 1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/1592778,1592778.0
"Efron D, Jarman FC, Barker MJ. Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication.  Journal of Paediatrics and Child Health 2000;36(5):457‐61. [PUBMED: 11036801] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11036801,11036801.0
"Shyu YC, Yuan SS, Lee SY, Yang CJ, Yang KC, Lee TL, et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan.  Schizophrenia Research 2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26363968,26363968.0
"Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD?.  European Child and Adolescent Psychiatry 2007;16(1):48‐57. [DOI: 10.1007/s00787‐006‐0574‐z; PUBMED: 16972117] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16972117,16972117.0
"Lee SH, Song DH, Kim BN, Joung YS, Ha EH, Cheon KA, et al. Variability of response time as a predictor of methylphenidate treatment response in Korean children with attention deficit hyperactivity disorder.  Yonsei Medical Journal 2009;50(5):650‐5. [DOI: 10.3349/ymj.2009.50.5.650; PMC2768239; PUBMED: 19881968]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19881968,19881968.0
"Newcorn JH, Stein MA, Cooper KM. Dose‐response characteristics in adolescents with attention‐deficit/hyperactivity disorder treated with OROS methylphenidate in a 4‐week, open‐label, dose‐titration study.  Journal of Child and Adolescent Psychopharmacology 2010;20(3):187‐96. [DOI: 10.1089/cap.2009.0102; PUBMED: 20578931] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20578931,20578931.0
"Coşkun M, Tutkunkardas MD, Zoroglu S. OROS methylphenidate‐induced skin eruptions. Journal of Child and Adolescent Psychopharmacology2009; Vol. 19, issue 5:593‐4. [DOI: 10.1089/cap.2009.0009; PUBMED: 19877987]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19877987,19877987.0
"Cohen HA, Ashkenazi A, Nussinovitch M, Gross S, Frydman M. Fixed drug eruption of the scrotum due to methylphenidate.  Annals of Pharmacotherapy 1992;26(11):1378‐9. [DOI: 10.1177/106002809202601107; PUBMED: 1477441]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/1477441,1477441.0
"Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.  Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/1121136,1121136.0
"Mostafavi SA, Mohammadi MR, Hosseinzadeh P, Eshraghian MR, Akhondzadeh S, Hosseinzadeh‐Attar MJ, et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?.  Iranian Journal of Psychiatry 2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23139692,23139692.0
"Findling RL. Open‐label treatment of comorbid depression and attentional disorders with co‐administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series.  Journal of Child and Adolescent Psychopharmacology 1996;6(3):165‐75. [DOI: 10.1089/cap.1996.6.165; PUBMED: 9231310]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9231310,9231310.0
"Golubchik P, Kodesh A, Weizman A. Attention‐deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?.  Clinical Neuropharmacology 2013;36(5):141‐5. [DOI: 10.1097/WNF.0b013e31829eb204; PUBMED: 24045603]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24045603,24045603.0
"Rashid J, Mitelman S. Methylphenidate and somatic hallucinations.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):945‐6. [DOI: 10.1097/CHI.0b013e318067fd7c; PUBMED: 17667474]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17667474,17667474.0
"Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salis O. Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder.  International Journal of Psychiatry in Clinical Practice 2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24994482,24994482.0
"Becker A, Roessner V, Breuer D, Döpfner M, Rothenberger A. Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD.  European Child and Adolescent Psychiatry 2011;20(Suppl 2):S267‐75. [DOI: 10.1007/s00787‐011‐0204‐2; PMC3180591; PUBMED: 21901415]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21901415,21901415.0
"Starr HL, Kemner J. Multicenter, randomized, open‐label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African‐American children with ADHD.  Journal of the National Medical Association 2005;97(10 Suppl):11S‐6S. [PMC2640623; PUBMED: 16350601] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16350601,16350601.0
"Yang R, Mao S, Zhang S, Li R, Zhao Z. Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22467793,22467793.0
"Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5‐year review.  Canadian Journal of Psychiatry 1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/10566114,10566114.0
"Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA.  Journal of Consulting and Clinical Psychology 2003;71(3):540‐52. [PUBMED: 12795577]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12795577,12795577.0
"Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, et al. Remission in children and adolescents diagnosed with attention‐deficit/ hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.  Journal of Child and Adolescent Psychopharmacology 2012;22(3):215‐25. [DOI: 10.1089/cap.2011.0006; PMC3373222; PUBMED: 22537358]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22537358,22537358.0
"Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long‐term stimulant medication treatment of attention‐deficit/hyperactivity disorder: results from a population‐based study.  Journal of Developmental and Behavioral Pediatrics 2014;27(1):448‐57. [PUBMED: 16511362]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16511362,16511362.0
"Feeney DJ, Klykylo WM. Medication‐induced seizures.  Journal of the American Academy of Child and Adolescent Psychiatry 1997;36(8):1018‐9. [DOI: 10.1097/00004583‐199708000‐00007; PUBMED: 9256580]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9256580,9256580.0
"Swanson JM, Hinshaw SP, Arnold LE, Gibbons RD, Marcus S, Hur K, et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17667479,17667479.0
"Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, et al. Bupropion versus methylphenidate in the treatment of attention‐deficit hyperactivity disorder.  Journal of the American Academy of Child and Adolescent Psychiatry 1995;34(5):649‐57. [DOI: 10.1097/00004583‐199505000‐00017; PUBMED: 7775360] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/7775360,7775360.0
"Preston RJ, Kollins SH, Swanson JM, Greenhill LL, Wigal T, Elliott GR, et al. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El‐Zein et al.  Cancer Letters 2005;230(2):292‐4. [DOI: 10.1016/j.canlet.2005.05.038; PUBMED: 16019134]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16019134,16019134.0
"Silva R, Tilker HA, Cecil JT, Kowalik S, Khetani V, Faleck H, et al. Open‐label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2004;14(4):555‐63. [DOI: 10.1089/cap.2004.14.555; PUBMED: 15662147]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15662147,15662147.0
"Harris MN, Voigt RG, Barbaresi WJ, Voge GA, Kilian JM, Weaver AL, et al. ADHD and learning disabilities in former late preterm infants: a population‐based birth cohort.  Pediatrics 2013;132(3):630‐6. [DOI: 10.1542/peds.2012‐3588; PMC3876753; PUBMED: 23979091]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23979091,23979091.0
"Artul S, Artoul F, Habib G, Nseir W, Bisharat B, Nijim Y. Severe recurrent pancreatitis in a child with ADHD after starting treatment with methylphenidate (Ritalin).  Case Reports in Gastrointestinal Medicine 2014;2014:319162. [DOI: 10.1155/2014/319162; PMC3965929; PUBMED: 24711932; PUBMED: 24711932]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24711932,24711932.0
"Man KK, Chan EW, Coghill D, Douglas I, Douglas I, Ip P, et al. Methylphenidate and the risk of trauma.  Pediatrics 2015;135(1):40‐8. [DOI: 10.1542/peds.2014‐1738; PUBMED: 25511122]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25511122,25511122.0
"Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.  Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11211367,11211367.0
"Yildiz Ö, Şişmanlar ŞG, Memik NÇ, Karakaya I, Ağaoğlu B. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.  Child Psychiatry and Human Development 2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21165694,21165694.0
Hinshaw SP. Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder.  Archives of General Psychiatry 1999;56(12):1088‐96. [PUBMED: 10591284] CENTRAL   Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/10591284,10591284.0
"Walitza S, Werner B, Romanos M, Warnke A, Gerlach M, Stopper H. Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?.  Environmental Health Perspectives 2007;115(6):936‐40. [DOI: 10.1289/ehp.9866; PMC1892117]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17589603,17589603.0
"Galland BC, Tripp EG, Gray A, Taylor BJ. Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study.  Sleep and Breathing 2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20440568,20440568.0
"Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program.  Journal of Abnormal Child Psychology 2000;28(6):507‐25. [PUBMED: 11104314] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11104314,11104314.0
"Gadow D, Nolan E, Sprafkin J, Sverd J. School observations of children with attention‐deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment.  Journal of Developmental and Behavioral Pediatrics 1995;16(3):167–76. [PUBMED: 7560119] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/7560119,7560119.0
"Buchmann J, Gierow W, Weber S, Hoeppner J, Klauer T, Benecke R, et al. Restoration of disturbed intracortical motor inhibition and facilitation in attention deficit hyperactivity disorder children by methylphenidate.  Biological Psychiatry 2007;62(9):963‐9. [DOI: 10.1016/j.biopsych.2007.05.010; PUBMED: 17719015]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17719015,17719015.0
"Yoshimasu K, Barbaresi WJ, Colligan RC, Voigt RG, Kilian JM, Weaver AL, et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders during adolescence: a population‐based birth cohort study.  Journal of Child Psychology and Psychiatry, and Allied Disciplines 2012;53(10):1036‐43. [DOI: 10.1111/j.1469‐7610.2012.02567.x; PMC3608464; PUBMED: 22647074]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22647074,22647074.0
"Görtz‐Dorten A, Breuer D, Hautmann C, Rothenberger A, Döpfner M. What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. European Child and Adolescent Psychiatry2011; Vol. 20, issue Suppl 2:S297‐307. [DOI: 10.1007/s00787‐011‐0207‐z; PMC3180627]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21901412,21901412.0
"Holtkamp K, Peters‐Wallraf B, Wuller S, Pfäaffle R, Herpertz‐Dahlmann B. Methylphenidate‐related growth impairment.  Journal of Child and Adolescent Psychopharmacology 2002;12(1):55‐61. [DOI: 10.1089/10445460252943579; PUBMED: 12014596]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12014596,12014596.0
"Altin M, El‐Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko N, et al. Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non‐Western countries.  Drugs in Context 2013;2013:212260. [DOI: 10.7573/dic.212260; PMC3884848]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24432046,24432046.0
"Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for Attention‐Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.  Progress in Neuro Psychopharmacology & Biological Psychiatry 2008;32(1):145‐9. [DOI: 10.1016/j.pnpbp.2007.07.025; PUBMED: 17765380] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17765380,17765380.0
"Gau SS, Shen HY, Soong WT, Gau CS. An open‐label, randomized, active‐controlled equivalent trial of osmotic release oral system methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan.  Journal of Child and Adolescent Psychopharmacology 2006;16(4):441‐55. [DOI: 10.1089/cap.2006.16.441; PUBMED: 16958569] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16958569,16958569.0
"Ghanizadeh A. A commentary on ""A young man with acute dilated cardiomyopathy associated with methylphenidate"".  Vascular Health and Risk Management 2009;5(2):525‐6. [DOI: 10.2147/VHRM.S5108]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19554092,19554092.0
"Tølløfsrud C, Hoel T. A young man with acute dilated cardiomyopathy.  Tidsskrift for Den Norske Laegeforening 2006;126(10):1338‐9. [PUBMED: 16715575]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16715575,16715575.0
"Katusic SK, Colligan RC, Barbaresi WJ, Schaid DJ, Jacobsen SJ. Potential influence of migration bias in birth cohort studies.  Mayo Clinic Proceedings 1998;73(11):1053‐61. [DOI: 10.4065/73.11.1053]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9818038,9818038.0
"Verret C, Gardiner P, Béliveau L. Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder.  Adapted Physical Activity Quarterly 2010;27(4):337‐51. [PUBMED: 20956839]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20956839,20956839.0
"Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study.  Journal of the American Academy of Child and Adolescent Psychiatry 2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19318991,19318991.0
"Efron D, Jarman FC, Barker MJ. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial.  Pediatrics 1997;100(4):662‐6. [PUBMED: 9310521] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/9310521,9310521.0
"Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, et al. Effect of transitioning from extended‐release methylphenidate onto osmotic, controlled‐release methylphenidate in children/adolescents with ADHD: results of a 3‐month non‐interventional study.  Current Medical Research and Opinion 2011;27(Suppl 2):35‐44. [DOI: 10.1185/03007995.2011.601733; PUBMED: 21787126]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21787126,21787126.0
"Golubchik P, Golubchik L, Sever JM, Weizman A. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.  International Clinical Psychopharmacology 2014;29(5):274‐8. [DOI: 10.1097/YIC.0000000000000034; PUBMED: 24743562]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24743562,24743562.0
"Davari‐Ashtiani R, Shahrbabaki ME, Razjouyan K, Amini H, Mazhabdar H. Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double‐blind and randomized trial.  Child Psychiatry and Human Development 2010;41(6):641‐8. [DOI: 10.1007/s10578‐010‐0193‐2; PUBMED: 20517641] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20517641,20517641.0
Ashkenasi A. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.  Pediatric Neurology 2011;45(6):381‐6. [DOI: 10.1016/j.pediatrneurol.2011.09.003; PUBMED: 22115000] CENTRAL   Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/22115000,22115000.0
"Jensen PS, Hinshaw SP, Kraemer HC, Leonora N, Newcorn JH, Abikoff HB, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11211363,11211363.0
"Gerwe M, Stollhoff K, Mossakowski J, Kuehle HJ, Goertz U, Schaefer C, et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial.  Attention Deficit and Hyperactivity Disorders 2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21432582,21432582.0
"Chandler ML, Barnhill JL, Gualtieri CT, Patterson DR. Tryptophan antagonism of stimulant‐induced tics.  Journal of Clinical Psychopharmacology 1989;9(1):69‐70. [PUBMED: 2708560]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/2708560,2708560.0
"Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial.  Australian and New Zealand Journal of Psychiatry 2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17464703,17464703.0
"Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH.  European Child and Adolescent Psychiatry 2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16220214,16220214.0
"Swanson JM, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw SP, et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary.  Journal of Attention Disorders 2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18573923,18573923.0
"Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers.  Journal of the American Academy of Child and Adolescent Psychiatry 1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/8885584,8885584.0
"Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained‐release methylphenidate.  Journal of Pediatrics 2004;144(5):675‐6. [DOI: 10.1016/j.jpeds.2003.12.039; PUBMED: 15127013]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15127013,15127013.0
"Tomás Vila M, Izquierdo Quevedo FJ, Cerdán Vera MT, Fernández A, Artás Figueres M, Revert Gomas M. Visual hallucinations caused by methylphenidate.  Anales de Pediatria 2010;72(3):229‐30. [DOI: 10.1016/j.anpedi.2009.10.013; PUBMED: 20097145]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20097145,20097145.0
"Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD.  Pediatric Neurology 2001;24(2):99‐102. [PUBMED: 11275457]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11275457,11275457.0
"Molina BS, Hinshaw SP, Eugene AL, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.  Journal of the American Academy of Child and Adolescent Psychiatry 2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23452682,23452682.0
"Coşkun M, Zoroglu S. A report of two cases of sexual side effects with OROS methylphenidate.  Journal of Child and Adolescent Psychopharmacology 2009;19(4):477‐9. [DOI: 10.1089/cap.2008.0161; PUBMED: 19702503]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19702503,19702503.0
"Valdizán Uson JR, Cánovas‐Martínez A, Lucas‐Taracena MT, Díaz‐Atienza F, Eddy‐Ives LS, Fernandez‐Jaen A, et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study.  Neuropsychiatric Disease and Treatment 2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23430373,23430373.0
"Hong J, Novick D, Treuer T, Montgomery W, Haynes VS, Wu S, et al. Predictors and consequences of adherence to the treatment of pediatric patients with attention‐deficit/hyperactivity disorder in Central Europe and East Asia.  Patient Preference and Adherence 2013;30(7):987‐95. [DOI: 10.2147/PPA.S50628; PMC3794850; PUBMED: 24124351]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24124351,24124351.0
"Weiss M, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, et al. Once‐daily multilayer‐release methylphenidate in a double‐blind, crossover comparison to immediate‐release methylphenidate in children with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2007;17(5):675‐88. [DOI: 10.1089/cap.2006.0101; PUBMED: 17979587] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17979587,17979587.0
"Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.  Journal of Developmental and Behavioral Pediatrics 2001;22(1):60‐73. [PUBMED: 11265923] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11265923,11265923.0
Gracious BL. Atrioventricular nodal re‐entrant tachycardia associated with stimulant treatment.  Journal of Child and Adolescent Psychopharmacology 1999;9(2):125‐8. [DOI: 10.1089/cap.1999.9.125; PUBMED: 10461823]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/10461823,10461823.0
"March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA).  Journal of Abnormal Child Psychology 2000;28(6):527‐41. [PUBMED: 11104315] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/11104315,11104315.0
Ghanizadeh A. Methylphenidate‐associated enuresis in attention deficit hyperactivity disorder.  Journal of Pediatric Urology 2008;4(4):306‐7. [DOI: 10.1016/j.jpurol.2007.10.001; PUBMED: 18644535]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/18644535,18644535.0
"Shang CY, Pan YL, Lin HY, Huang LW, Gau SS. An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26222447,26222447.0
"Garg J, Arun P, Chavan BS. Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder.  Indian Pediatrics 2014;51(7):550‐4. [PUBMED: 25031133] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25031133,25031133.0
"Coşkun M, Zoroglu S. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination.  Journal of Clinical Psychopharmacology 2008;28(6):723‐5. [DOI: 10.1097/JCP.0b013e31818ce752; PUBMED: 19011457]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19011457,19011457.0
"Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials.  Clinical Therapeutics 2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19808143,19808143.0
"Ramasamy R, Dadhich P, Dhingra A, Lipshultz L. Case report: testicular failure possibly associated with chronic use of methylphenidate.  F1000Research 2014;3:207. [DOI: 10.12688/f1000research.5163.1; PMC4215747; PUBMED: 25383187]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25383187,25383187.0
"Montiel‐Nava C, Peña JA, Espina‐Mariñes G, Ferrer‐Hernandez ME, López‐Rubio A, Puertas‐Sánchez S, et al. A pilot study of methylphenidate and parent training in the treatment of children with attention deficit hyperactivity disorder [Estudio piloto de metilfenidato y entrenamiento a padres en el tratamiento de niños con trastorno por déficit de atención‐hiperactividad].  Revista de Neurologia 2002;35(3):201‐5. [PUBMED: 12235578]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12235578,12235578.0
"Goez HR, Scott O, Nevo N, Bennett‐Back O, Zelnik N. Using the test of variables of attention to determine the effectiveness of modafinil in children with attention‐deficit hyperactivity disorder (ADHD): a prospective methylphenidate‐controlled trial.  Journal of Child Neurology 2012;27(12):1547‐52. [DOI: 10.1177/0883073812439101; PUBMED: 22447850] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22447850,22447850.0
"Li JJ, Li ZW, Wang SZ, Qi FH, Zhao L, Lv H, et al. Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder. Psychopharmacology2011; Vol. 216, issue 4:501‐9. [DOI: 10.1007/s00213‐011‐2238‐z; PUBMED: 21416235] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21416235,21416235.0
"Schulz E, Fleischhaker C, Hennighausen K, Heiser P, Haessler F, Linder M, et al. A randomized, rater‐blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention‐deficit hyperactivity disorder under different breakfast conditions over 2 weeks.  Attention Deficit and Hyperactivity Disorders 2010;2(3):133‐8. [DOI: 10.1007/s12402‐010‐0031‐1; PUBMED: 21432599] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21432599,21432599.0
"Fernández‐Fernández MA, Rufo‐Campos M, Mateos‐Checa R, Muñoz‐Cabello B, Madruga‐Garrido M, Blanco‐Martínez B. Infantile psychosis secondary to methylphenidate.  Revista de Neurologia 2011;52(7):446‐7. [PUBMED: 21425116]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21425116,21425116.0
"Wang LJ, Wu CC, Lee SY, Tsai YF. Salivary neurosteroid levels and behavioural profiles of children with attention‐deficit/hyperactivity disorder during six months of methylphenidate treatment.  Journal of Child and Adolescent Psychopharmacology 2014;24(6):336‐40. [DOI: 10.1089/cap.2013.0122; PUBMED: 24956271]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24956271,24956271.0
"Hechtman L, Abikoff H, Klein RG, Weiss G, Respitz C, Kouri J, et al. Academic achievement and emotional status of children with ADHD treated with long‐term methylphenidate and multimodal psychosocial treatment.  Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(7):812‐9. [DOI: 10.1097/01.chi.0000128796.84202.eb; PUBMED: 15213582] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15213582,15213582.0
"Cockcroft K, Ashwal J, Bentley A. Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD).  African Journal of Psychiatry 2009;12(4):275‐9. [PUBMED: 20033109]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20033109,20033109.0
"Rothenberger A, Becker A, Breuer D, Döpfner M. An observational study of once‐daily modified‐release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.  European Child and Adolescent Psychiatry 2011;20(Suppl 2):257‐65. [DOI: 10.1007/s00787‐011‐0203‐3; PMC3180635]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21901416,21901416.0
"Karabekiroglu K, Yazgan Y M, Dedeoglu C. Can we predict short‐term side effects of methylphenidate immediate‐release?.  International Journal of Psychiatry in Clinical Practice 2008;12(1):48‐54. [DOI: 10.1080/13651500701435954]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24916497,24916497.0
Efron D. Methylphenidate versus dextroamphetamine in ADHD.  Journal of the American Academy of Child and Adolescent Psychiatry 1999;38(5):500. [PUBMED: 10230180] CENTRAL   Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/10230180,10230180.0
"Kim E, Cheon KA, Joung YS, Kim JY, Song DH. The relationship between symptomatic and functional changes of Korean children and adolescents with attention‐deficit/hyperactivity disorder treated with osmotic‐controlled release oral delivery system‐methylphenidate. Clinical Neuropharmacology2015; Vol. 38, issue 1:30‐5. [DOI: 10.1097/WNF.0000000000000064; PUBMED: 25580917]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25580917,25580917.0
"Yatsuga C, Toyohisa D, Fujisawa TX, Nishitani S, Shinohara K, Matsuura N, et al. No association between catechol‐O‐methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children.  Brain and Development 2014;36(7):620‐5. [DOI: 10.1016/j.braindev.2013.08.006; PUBMED: 24035255]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24035255,24035255.0
"Nieweg EH. Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek].  Tijdschrift voor Psychiatrie 2010;52(4):245‐54. [PUBMED: 20503165]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20503165,20503165.0
"Song DH, Choi S, Joung YS, Ha EH, Kim BN, Shin YJ, et al. Titrating optimal dose of osmotic‐controlled release oral delivery (OROS)‐methylphenidate and its efficacy and safety in Korean children with ADHD: a multisite open labeled study. Psychiatry Investigation2012; Vol. 9, issue 3:257‐62. [DOI: 10.4306/pi.2012.9.3.257; PMC3440475]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22993525,22993525.0
"Arnold LE, Chuang S, Davies M, Abikoff HB, Conners CK, Elliott GR, et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures.  Journal of Abnormal Child Psychology 2004;32(1):39‐51. [PUBMED: 14998110] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/14998110,14998110.0
"Wang LJ, Huang YS, Hsiao CC, Chiang YL, Wu CC, Shang ZY, et al. Salivary dehydroepiandrosterone, but not cortisol, is associated with attention deficit hyperactivity disorder.  World Journal of Biological Psychiatry 2011;12(2):99‐109. [DOI: 10.3109/15622975.2010.512090; PUBMED: 20822373]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20822373,20822373.0
"Aguilera‐Albesa S, Yoldi‐Petri ME, Molins‐Castiella T, Durá‐Travé T. Hallucinations caused by the introduction of methylphenidate at low doses.  Revista de Neurologia 2010;51(4):254‐5. [PUBMED: 20648469]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20648469,20648469.0
"Zheng Y, Liang JM, Gao HY, Yang ZW, Jia FJ, Liang YZ, et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder.  Chinese Medical Journal 2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26608976,26608976.0
"Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention‐deficit/hyperactivity disorder.  Archives of General Psychiatry 2007;64(2):218‐24. [DOI: 10.1001/archpsyc.64.2.218; PUBMED: 17283289]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17283289,17283289.0
"Loo SK, Bilder R, Cho AL, Sturm A, Cowen J, Welker PW, et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder.  Journal of the American Academy of Child and Adolescent Psychiatry 2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/27453081,27453081.0
"Greenhill L, Puig‐Antich J, Goetz R, Hanlon C, Davies M. Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity.  Sleep 1983;6(2):91‐101. [PUBMED: 6878986]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/6878986,6878986.0
"Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidate‐induced visual hallucinations.  Neuropediatrics 2011;42(1):30‐1. [DOI: 10.1055/s‐0031‐1275738; PUBMED: 21500140]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21500140,21500140.0
"Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system.  Current Medical Research and Opinion 2009;25(12):3001‐10. [DOI: 19849639; PUBMED: 10.1185/03007990903388797] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19849639,19849639.0
"Maayan L, Paykina N, Fried J, Strauss T, Gugga SS, Greenhill L. The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate.  Journal of Child and Adolescent Psychopharmacology 2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19374023,19374023.0
"Lyon GJ, Samar SM, Conelea C, Trujillo MR, Lipinski CM, Bauer CC, et al. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention‐deficit/hyperactivity disorder and Tourette's disorder.  Journal of Child and Adolescent Psychopharmacology 2010;20(4):283‐9. [DOI: 10.1089/cap.2010.0032] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20807066,20807066.0
"Tzang RF, Wang YC, Yeh CB, Hsu CD, Liang HY, Yang PC, et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22250610,22250610.0
"Na KS, Lee SI, Hong SD, Kim JH, Shim SH, Choi J, et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study.  International Clinical Psychopharmacology 2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23587983,23587983.0
"Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH.  European Child and Adolescent Psychiatry 2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16220213,16220213.0
"Döpfner M, Görtz‐Dorten A, Breuer D, Rothenberger A. An observational study of once‐daily modified‐release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.  European Child and Adolescent Psychiatry 2011;20(Suppl 2):S243‐55. [DOI: 10.1007/s00787‐011‐0202‐4; PMC3180616; PUBMED: 21901417]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21901417,21901417.0
Hechtman L. Treatment of ADHD in patients unresponsive to methylphenidate.  Journal of Psychiatry and Neuroscience 2011;36(3):216. [DOI: 10.1503/jpn.110020; PMC3080516]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/21496443,21496443.0
"Haertling F, Mueller B, Bilke‐Hentsch O. Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions.  Attention Deficit and Hyperactivity Disorders 2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25346231,25346231.0
"Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.  Sleep 2006;29(12):1573‐85. [PUBMED: 17252888] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17252888,17252888.0
"Famularo R, Fenton T. The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: a preliminary report.  Journal of Clinical Psychiatry 1987;48(3):112‐4. [PUBMED: 3818551]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/3818551,3818551.0
"Ghanizadeh A, Aghakhani K. Photophobia and methylphenidate.  Psychopharmacology Bulletin 2008;41(1):171‐3. [PUBMED: 18362880]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18362880,18362880.0
"Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17667480,17667480.0
"Vashi NA, Souza A, Cohen N, Franklin B, Cohen DE. Allergic contact dermatitis caused by methylphenidate.  Contact Dermatitis 2011;65(3):183‐85. [DOI: 10.1111/j.1600‐0536.2011.01949.x; PUBMED: 21827513]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21827513,21827513.0
"Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.  Annals of Pharmacotherapy 2008;42(1):24‐31. [DOI: 10.1345/aph.1K143; PUBMED: 18042808]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18042808,18042808.0
"Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schauble B. Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD.  Expert Review of Neurotherapeutics 2011;11(4):499‐508. [DOI: 10.1586/ern.11.18]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21469923,21469923.0
"Döpfner M, Ose C, Fischer R, Ammer R, Scherag A. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial.  Journal of Child & Adolescent Psychopharmacology 2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21790298,21790298.0
"Cho S‐C, Kim B‐N, Cummins TD, Kim J‐W, Bellgrove MA. Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21628343,21628343.0
"McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once‐daily OROS methylphenidate is safe and well tolerated in adolescents with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2006;16(3):351‐6. [DOI: 10.1089/cap.2006.16.351; PUBMED: 16768642] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16768642,16768642.0
MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder.  Archives of General Psychiatry 1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] CENTRAL,https://www.ncbi.nlm.nih.gov/pubmed/10591283,10591283.0
"Wang LJ, Hsiao CC, Huang YS, Chiang YL, Ree SC, Chen YC, et al. Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate.  Psychoneuroendocrinology 2011;36(8):1209‐16. [DOI: 10.1016/j.psyneuen.2011.02.014; PUBMED: 21411231] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21411231,21411231.0
"Golubchik P, Sever J, Weizman A. Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.  International Clinical Psychopharmacology 2014;29(4):212‐5. [DOI: 10.1097/YIC.0000000000000029; PMC4047304; PUBMED: 24448460]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24448460,24448460.0
"Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S. Buspirone versus methylphenidate in the treatment of children with attention‐ deficit/ hyperactivity disorder: randomized double‐blind study.  Acta Medica Iranica 2012;50(11):723‐8. [PUBMED: 23292622] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23292622,23292622.0
"Lee WJ, Lee TA, Pickard AS, Caskey RN, Schumock GT. Drugs associated with adverse events in children and adolescents.  Pharmacotherapy 2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24990656,24990656.0
"Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan.  Journal of Clinical Psychiatry 2008;69(1):131‐40. [PUBMED: 18312048]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/18312048,18312048.0
"Arnold LE, Bozzolo DR, Hodgkins P, McKay M, Beckett‐Thurman L, Greenbaum M, et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion.  Current Medical Research and Opinion 2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19916704,19916704.0
"Lewis H, Lewis J. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma. ADHD Attention Deficit and Hyperactivity Disorders2012; Vol. 4, issue 1:37‐9. [DOI: 10.1007/s12402‐012‐0071‐9; PUBMED: 22311620]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22311620,22311620.0
"Tomás Vila M, Aleu Pérez‐Gramunt M, Beseler Soto B, Benac Prefasi M, Pantoja Martínez J, Pitarch Castellano I. Methylphenidate and sleep: results of a multicentre study on a population of children with attention deficit hyperactivity disorder.  Anales de Pediatria 2010;73(2):78‐83. [DOI: 10.1016/j.anpedi.2010.05.013; PUBMED: 20605120]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20605120,20605120.0
"Zhang H, Du M, Zhuang S. Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD.  Neuropediatrics 2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20799150,20799150.0
"Ilgenli TF, Congologlu A, Ozturk C, Turkbay T, Akpinar O, Kilicaslan F. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder.  Advances in Therapy 2007;24(1):182‐8. [PUBMED: 17526476]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17526476,17526476.0
"Arabgol F, Panaghi L, Nikzad V. Risperidone versus methylphenidate in treatment of preschool children with attention‐deficit hyperactivity disorder.  Iranian Journal of Pediatrics 2015;25(1):1‐6. [DOI: 10.5812/ijp.265; PMC4505976]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26199694,26199694.0
"Lee MJ, Yang KC, Shyu YC, Yuan SS, Yang CJ, Lee SY, et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan.  Journal of Affective Disorders 2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26433758,26433758.0
"Keating GM. Methylphenidate transdermal system in attention‐deficit hyperactivity disorder in adolescents: profile report. Drugs in R&D. G.M. Keating, Adis, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. E‐mail: demail@springer.com, 2012; Vol. 12, issue 3:171‐3. [DOI: 10.2165/11207490‐000000000‐00000; PMC3585903; PUBMED: 22934753] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22934753,22934753.0
"Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.  Journal of Child and Adolescent Psychopharmacology 2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23234585,23234585.0
"Işeri E, Kilic BG, Senol S, Karabacak NI. Effects of methylphenidate on leptin and appetite in children with attention‐deficit hyperactivity disorder: an open label trial.  Methods and Findings in Experimental and Clinical Pharmacology 2007;29(1):47‐52. [DOI: 10.1358/mf.2007.29.1.1063491; PUBMED: 17344944]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17344944,17344944.0
"Sverd J, Gadow KD, Nolan EE, Sprafkin J, Ezor SN. Methylphenidate in hyperactive boys with comorbid tic disorder: I. Clinic evaluations. Advances in Neurology1992; Vol. 58:271‐81. [PUBMED: 1414633]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/1414633,1414633.0
"Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3‐year follow‐up of the NIMH MTA study.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17667478,17667478.0
"McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention‐deficit hyperactivity disorder: a retrospective cohort study of children, adolescents and young adults using the general practice research database.  Drug Safety 2009;32(11):1089‐96. [DOI: 10.2165/11317630‐000000000‐00000; PUBMED: 19810780]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19810780,19810780.0
"Spencer TJ, Faraone SV, Lerner M, Cooper KM, Zimmerman B. Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply.  Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17314713,17314713.0
"Kim BN, Kim YN, Cheong US, Kim JW, Hwang JW, Shin MS, et al. Switching from Methylphenidate‐Immediate Release (MPH‐IR) to Methylphenidate‐OROS (OROS‐MPH): a multi‐center, open‐label study in Korea.  Clinical Psychopharmacology and Neuroscience 2011;9(1):29‐35. [DOI: 10.9758/cpn.2011.9.1.29; PMC3568652; PUBMED: 23430964]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23430964,23430964.0
"Karaman MG, Atalay F, Tufan AE, Erdogan A. Pulmonary arterial hypertension in an adolescent treated with methylphenidate.  Journal of Child & Adolescent Psychopharmacology 2010;20(3):229‐31. [DOI: 10.1089/cap.2009.0095; PUBMED: 20578938]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20578938,20578938.0
"Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.  Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12874489,12874489.0
"Klein RG, Abikoff H, Hechtman L, Weiss G. Design and rationale of controlled study of long‐term methylphenidate and multimodal psychosocial treatment in children with ADHD.  Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(7):792‐801. [DOI: 10.1097/01.chi.0000128798.91601.fe; PUBMED: 15213580] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15213580,15213580.0
"Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern.  Journal of Paediatrics and Child Health 2003;39(3):180‐5. [PUBMED: 12654140]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12654140,12654140.0
"Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double‐blind trial.  Human Psychopharmacology 2010;25(7‐8):560‐5. [DOI: 10.1002/hup.1154; PUBMED: 21312290] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21312290,21312290.0
"Kim Y, Kim B, Chang JS, Kim BN, Cho SC, Hwang JW. Parental quality of life and depressive mood following methylphenidate treatment of children with attention‐deficit hyperactivity disorder.  Psychiatry and Clinical Neurosciences 2014;68(7):506‐14. [DOI: 10.1111/pcn.12155; PUBMED: 24417707]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24417707,24417707.0
"Ghanizadeh A, Haghighat R. Nortriptyline for treating enuresis in ADHD‐‐a randomized double‐blind controlled clinical trial.  Pediatric Nephrology 2012;27(11):2091‐7. [DOI: 10.1007/s00467‐012‐2211‐z; PUBMED: 22700161] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22700161,22700161.0
"Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schwartz J. Anxiety and depression symptoms and response to methylphenidate in children with attention‐deficit hyperactivity disorder and tic disorder.  Journal of Clinical Psychopharmacology 2002;22(3):267‐74. [PUBMED: 12006897] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12006897,12006897.0
"Spencer T, Biederman J, Wright V, Danon M. Growth deficits in children treated with desipramine: a controlled study.  Journal of the American Academy of Child & Adolescent Psychiatry 1992;31(2):235‐43. [DOI: 10.1097/00004583‐199203000‐00009; PUBMED: 1564024]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/1564024,1564024.0
"Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.  Journal of Child and Adolescent Psychopharmacology 2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19877973,19877973.0
"Ayaz M, Ayaz AB, Soylu N, Yüksel S. Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25010598,25010598.0
Trugman JM. Cerebral arteritis and oral methylphenidate.  Lancet 1988;1(8585):584‐5. [PUBMED: 2894511]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/2894511,2894511.0
"Rapport MD, Loo S, Isaacs P, Goya S, Denney C, Scanlan S. Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention‐deficit/hyperactivity disorder.  Behavior Modification 1996;20(4):428‐50. [DOI: 10.1177/01454455960204004; PUBMED: 8875814] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/8875814,8875814.0
"Truer T, Feng Q, Desaiah D, Altin M, Wu S, El‐Shafei A, et al. Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention‐deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates.  International Journal of Clinical Practice 2014;68(9):1152‐62. [DOI: 10.1111/ijcp.12437; PUBMED: 24703228]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24703228,24703228.0
"Vincent J, Varley CK, Leger P. Effects of methylphenidate on early adolescent growth.  American Journal of Psychiatry 1990;147(4):501‐2. [DOI: 10.1176/ajp.147.4.501; PUBMED: 2316739]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/2316739,2316739.0
"Park S, Kim BN, Kim JW, Shin MS, Cho SC, Kim JH, et al. Neurotrophin 3 genotype and emotional adverse effects of osmotic‐release oral system methylphenidate (OROS‐MPH) in children with attention‐deficit/hyperactivity disorder.  Journal of Psychopharmacology 2014;28(3):220‐6. [DOI: 10.1177/0269881113480989; PUBMED: 23471121]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23471121,23471121.0
"Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.  Pediatrics 2009;124(1):e75‐80. [DOI: 10.1542/peds.2008‐3138; PMC3856396; PUBMED: 19564272]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19564272,19564272.0
"Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.  BMC Psychiatry 2004;4(9):1‐6. [DOI: 10.1186/1471‐244X‐4‐9; PMC400741; PUBMED: 15070418] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/15070418,15070418.0
"Arcieri R, Germinario EP, Bonati M, Masi G, Zuddas A, Vella S, et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.  Journal of Child and Adolescent Psychopharmacology 2012;22(6):423‐31. [PUBMED: 23362511]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23362511,23362511.0
"Breuer D, Görtz‐Dorten A, Rothenberger A, Döpfner M. Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings.  European Child and Adolescent Psychiatry 2011;20(Suppl 2):S289‐96. [DOI: 10.1007/s00787‐011‐0206‐0; PMC3180560; PUBMED: 21901413]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21901413,21901413.0
"Karapinar U, Saglam O, Dursun E, Cetin B, Salman N, Sahan M. Sudden hearing loss associated with methylphenidate therapy.  European Archives of Otorhinolaryngology 2014;271(1):199‐201. [DOI: 10.1007/s00405‐013‐2763‐y; PUBMED: 24141471]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24141471,24141471.0
"Akhondzadeh S, Tavakolian R, Davari‐Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.  Progress in Neuro Psychopharmacology and Biological Psychiatry 2003;27(5):841‐5. [DOI: 10.1016/S0278‐5846(03)00117‐9; PUBMED: 12921918] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12921918,12921918.0
"Wigal S, Childress A, Belden H, Berry S. NWP06, an extended‐release oral suspension of methylphenidate, improved attention‐deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.  Journal of Child and Adolescent Psychopharmacology 2013;23(1):3‐10. [DOI: 10.1089/cap.2012.0073; PMC3696913] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23289899,23289899.0
"Confino‐Cohen R, Goldberg A. Successful desensitization of methylphenidate‐induced rash.  Journal of Child and Adolescent Psychopharmacology 2005;15(4):703‐5. [DOI: 10.1089/cap.2005.15.703; PUBMED: 16190802]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16190802,16190802.0
"Findling RL, Turnbow J, Burnside J, Melmed R, Civil R, Li Y. A randomized, double‐blind, multicenter, parallel‐group, placebo‐controlled, dose‐optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents.  CNS Spectrums 2010;15(7):419‐30. [PUBMED: 20625364] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20625364,20625364.0
"Khodadust N, Jalali A‐H, Ahmadzad‐Asl M, Khademolreza N, Shirazi E. Comparison of two brands of methylphenidate (Stimdate® vs. Ritalin®) in children and adolescents with attention deficit hyperactivity disorder: a double‐blind, randomized clinical trial. Iranian Journal of Psychiatry and Behavioral Sciences2012; Vol. 6, issue 1:26‐32. [PMC3939941] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24644466,24644466.0
"Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long‐term stimulant medication treatment of attention‐deficit/hyperactivity disorder: results from a population‐based study.  Journal of Developmental and Behavioral Pediatrics 2006;27(1):1‐10. [PUBMED: 16511362]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16511362,16511362.0
"Mohammadi MR, Mostafavi SA, Keshavarz SA, Eshraghian MR, Hosseinzadeh P, Hosseinzadeh‐Attar MJ, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial.  Iranian Journal of Psychiatry 2012;7(2):87‐92.  CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22952551,22952551.0
"Zelnik N, Terkel‐Dawer R. The clinical profile of children with ADHD that require OROS‐methylphenidate combined with shorter‐acting formulations.  ADHD Attention Deficit and Hyperactivity Disorders 2015;7(4):313‐8. [DOI: 10.1007/s12402‐015‐0168‐z; PUBMED: 25838111]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/25838111,25838111.0
"Durá‐Travé T, Yoldi‐Petri ME, Gallinas‐Victoriano F, Zardoya‐Santos P. Effects of osmotic‐release methylphenidate on height and weight in children with attention‐deficit hyperactivity disorder (ADHD) following up to four years of treatment. Journal of Child Neurology2012; Vol. 27, issue 5:604‐9. [DOI: 10.1177/0883073811422752; PUBMED: 22190507]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22190507,22190507.0
"Arnold LE, Elliott M, Sachs L, Bird H, Kraemer HC, Wells KC, et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD.  Journal of Consulting and Clinical Psychology 2003;71(4):713‐27. [PUBMED: 12924677] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12924677,12924677.0
"Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.  BMJ 2016;353:i2550. [DOI: 10.1136/bmj.i2550]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/27245699,27245699.0
"Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ. Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in Korean children with attention‐deficit/Hyperactivity disorder: is there an interaction?. Journal of Child and Adolescent Psychopharmacology2012; Vol. 22, issue 5:343‐52. [DOI: 10.1089/cap.2011.0076; PUBMED: 23083021]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23083021,23083021.0
"Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study.  Journal of the American Academy of Child and Adolescent Psychiatry 2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16175106,16175106.0
Carey WB. What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits.  Pediatrics 2000;105(4):863‐4. [PUBMED: 10742336]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/10742336,10742336.0
"Yu ZJ, Parker‐Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention‐deficit/hyperactivity disorder.  Current Psychiatry Reports 2010;12(2):111‐5. [DOI: 10.1007/s11920‐010‐0093‐y; PUBMED: 20425295]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20425295,20425295.0
Greenberg LM. An objective measure of methylphenidate response: clinical use of the MCA.  Psychopharmacology Bulletin 1987;23(2):279‐82. [PUBMED: 3615775]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/3615775,3615775.0
"Ghanizadeh A. Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder.  Journal of Clinical Psychopharmacology 2008;28(6):725‐6. [DOI: 10.1097/JCP.0b013e31818ce741; PUBMED: 19011458]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19011458,19011458.0
"Wigal SB, Gupta S, Heverin E, Starr HL. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention‐deficit/hyperactivity disorder.  Journal of Child and Adolescent Psychopharmacology 2011;21(3):255‐63. [DOI: 10.1089/cap.2010.0083; PUBMED: 21663428] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21663428,21663428.0
Adrian N. Explosive outbursts associated with methylphenidate.  Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(6):618‐9. [DOI: 10.1097/00004583‐200106000‐00002; PUBMED: 11392335]CENTRAL    Google Scholar,https://www.ncbi.nlm.nih.gov/pubmed/11392335,11392335.0
"Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial.  Human Psychopharmacology 2010;25(7‐8):530‐5. [DOI: 10.1002/hup.1148; PUBMED: 20860068] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20860068,20860068.0
"Winsberg BG, Kupietz SS, Sverg J, Hungund BL, Young NL. Methylphenidate oral dose plasma concentrations and behavioral response in children.  Psychopharmacology 1982;76(4):329‐32. [PUBMED: 6812106] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/6812106,6812106.0
"Williamson LB, Gower M, Ulzen T. Clinical case rounds in child and adolescent psychiatry: enuresis and ADHD in older children and an adolescent treated with stimulant medication: a case series.  Journal of the Canadian Academy of Child and Adolescent Psychiatry 2011;20(1):53‐5. [PMC3024723]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21286368,21286368.0
"Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial.  Journal of Child and Adolescent Psychopharmacology 2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/12880507,12880507.0
"Dittmann RW, Banaschewski T, Schacht A, Wehmeier PM. Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD‐related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment.  Attention Deficit and Hyperactivity Disorders 2014;6(2014):291‐302. [DOI: 10.1007/s12402‐014‐0136‐z; PUBMED: 24705867]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24705867,24705867.0
"Warshaw EM, Squires L, Li Y, Civil R, Paller AS. Methylphenidate transdermal system: a multisite, open‐label study of dermal reactions in pediatric patients diagnosed with ADHD.  Primary Care Companion to the Journal of Clinical Psychiatry 2010;12(6):e1‐e9. [DOI: 10.4088/PCC.10m00996pur; NCT00434213; PMC3067997; PUBMED: 21494336]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21494336,21494336.0
"Golubchik P, Sever J, Weizman A, Zalsman G. Methylphenidate treatment in pediatric patients with attention‐deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report.  Clinical Neuropharmacology 2011;34(3):108‐10. [DOI: 10.1097/WNF.0b013e31821f4da9; PUBMED: 21586916]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/21586916,21586916.0
"Wilens T, Biederman J, Lerner M, Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study.  Journal of Clinical Psychopharmacology 2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/14709945,14709945.0
"Peyre H, Speranza M, Cortese S, Wohl M, Purper‐Ouakil D. Do ADHD children with and without child behavior checklist‐dysregulation profile have different clinical characteristics, cognitive features, and treatment outcomes?.  Journal of Attention Disorders 2012;19(1):63‐71. [DOI: 10.1177/1087054712452135; PUBMED: 22837549]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22837549,22837549.0
"Zeni CP, Guimarães AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention‐deficit/hyperactivity disorder.  American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2007;144B(3):391‐4. [DOI: 10.1002/ajmg.b.30474; PUBMED: 17171656]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17171656,17171656.0
"Maia CR, Matte BC, Ludwig HT, Rohde LA. Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder.  European Child and Adolescent Psychiatry 2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/17846812,17846812.0
"Schertz M, Adesman AR, Alfieri NE, Bienkowski RS. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.  Pediatrics 1996;98(4 Pt 1):763‐9. [PUBMED: 8885958]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/8885958,8885958.0
"Corrigall R, Ford T. Methylphenidate euphoria.  Journal of the American Academy of Child and Adolescent Psychiatry 1996;35(11):1421. [DOI: 10.1097/00004583‐199611000‐00005; PUBMED: 8936903]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/8936903,8936903.0
"Walitza S, Kampf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, et al. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.  Toxicology Letters 2009;184(1):38‐43. [DOI: 10.1016/j.toxlet.2008.10.011]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/19015014,19015014.0
"Hansen L, Thomsen PH. How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?.  Ugeskr Laeger 2005;167(48):4555‐9. [PUBMED: 16324436]CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16324436,16324436.0
"Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention‐deficit/hyperactivity disorder.  Archives of Pediatrics and Adolescent Medicine 2006;160(1):82‐90. [DOI: 10.1001/archpedi.160.1.82; PUBMED: 16389216] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/16389216,16389216.0
"Galland BC, Tripp EG, Taylor BJ. The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study.  Journal of Sleep Research 2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] CENTRAL   Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/20050995,20050995.0
